Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 265 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby November 25, 2020 Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... March 2, 2021 Combination immunotherapy for advanced bowel cancer approved for NHS in England June 16, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel April 22, 2022 Load more HOT NEWS Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... EMA Recommends Granting a Marketing Authorisation for Tucatinib FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection NCI Expands Repository of Cancer Research Models: A Conversation with Drs....
